Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency

Abstract excerpt

Abstract The magnitude of weight reduction in the SURMOUNT-1 trial of the dual GLP-1 and GIP receptor agonist tirzepatide suggests that this treatment may be particularly effective in addressing the treatment needs of people with severe obesity (body mass index >40 kg m−2), some of whom may carry rare penetrant genetic variants. Here we investigated the clinical response of men and women in the SURMOUNT-1 trial...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Biochemical Analysis and Sensing Techniques
• Share to Diabetes Treatment and Management
• Share to Regulation of Appetite and Obesity